Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

White Paper

Tech Sheet on Pregabalin API

Tech Sheet on Pregabalin API

Pregabalin's precise mechanism of action is not fully understood, but studies suggest that it binds to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system. This binding modulates the release of excitatory neurotransmitters and prevents the trafficking of the alpha2-delta subunit. Although pregabalin is structurally related to GABA, it does not directly bind to GABA or benzodiazepine receptors.

Dr. Reddy's API Offering

  • Offers crystalline form-I i.e., Innovator form.
  • The control strategy for the API impurity profile has been designed through quality-by- design (QbD) based development.
  • Lactam impurity levels are not detected thus able to achieve USP/ EP compliance after milling - opening a possibility for a wide range of delivery systems like dispersible films, oral disintegrating tablets, etc.

We manufacture Pregabalin API at our cGMP API manufacturing facility, which was successfully inspected by international regulatory authorities - WHO GMP, KFDA, PMDA, ANVISA, and USFDA.

To know more about our API offerings, please read the Tech sheet on Pregabalin API by filling the contact form below.

Explore other Whitepapers:

Know More

Download Now

Please fill the Contact form below in order to view the white paper

Email us: api@drreddys.com | +91 40 49002222

Disclaimer

No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.